Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yazd Medical University
ClinicalTrials.gov Identifier:
NCT01542411
First received: February 25, 2012
Last updated: March 1, 2012
Last verified: February 2012

February 25, 2012
March 1, 2012
April 2008
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01542411 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment
Not Provided

This study evaluated the effect of anticoagulant treatment on the live-birth rate in women with a history of at least two continuous unexplained miscarriages or thrombophilia. It also compared two methods of treatment with aspirin and aspirin plus heparin.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

This project evaluated 520 women with unexplained recurrent miscarriage for four years. They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute. Women with unexplained recurrent miscarriage included in this study

Recurrent Pregnancy Loss
Not Provided
  • recurrent pregnancy loss
  • thrombophilia, aspirin
  • heparin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
520
Not Provided
Not Provided

Inclusion Criteria:

  • unexplained recurrent miscarriage,
  • women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A), and methyltetrahydrofolate reductase C677T (MTHFR C677T)

Exclusion Criteria:

  • abnormal karyotypes of both partners,
  • uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,
  • abnormal ovaries and abnormal endocrine tests.
Female
19 Years to 35 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
NCT01542411
2362
Yes
Yazd Medical University
Yazd Medical University
Not Provided
Principal Investigator: Tahere Jahaninejad, MSC Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran
Yazd Medical University
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP